Terumo's MicroVention Casper Carotid Stent Evaluated for Safety and Efficacy at 90 Days

 

August 29, 2018—In a retrospective analysis of prospectively collected data evaluating the safety and efficacy of the Casper carotid stent (MicroVention, Inc., a subsidiary of Terumo), the device demonstrated safety and efficacy in the treatment of carotid stenosis with no technical failures and no adverse neurological events in the 90-day follow-up period. Casper's double-layer structure combines adequate plaque scaffolding with high vessel adaptability, concluded Sebastian J. Mutzenbach, MD, et al in Journal of NeuroInterventional Surgery (JNIS; 2018;10:869–873).

As summarized in JNIS, the study was composed of 138 patients (25.4% women; median age, 71 years) who underwent Casper stent implantation for carotid artery stenosis between January 2014 and February 2017. Eligibility criteria included stenosis > 70% of vessel diameter (or > 50% diameter with ulceration) in symptomatic patients or asymptomatic patients with > 80% stenosis at the carotid bifurcation or in the proximal internal carotid artery. A distal embolic protection device was used for all procedures.

The primary endpoint was the rate of 90-day major adverse neurological events, defined as minor stroke, major stroke, or death by independent neurological assessment.

The investigators reported the following in JNIS:

  • Stent deployment was successfully completed in all cases without documented technical failure.
  • During a procedure, there was one thromboembolic occlusion of a small distal branch of the anterior cerebral artery that was resolved with administration of systemic recombinant tissue plasminogen activator.
  • At 90 days, there were no adverse neurological events or mortalities.
  • Postprocedure cerebral MRI showed new ischemic lesions, all clinically silent, in 6.5% of patients.

In July, Erasmia Broussalis, MD, et al published findings from a study online in JNIS that concluded that using the Casper stent in combination with a distal embolic protection device is safe and results in a lower rate of periprocedural cerebral diffusion-weighted imaging lesion burden compared with reported results for historic controls. The Caspar device is not cleared nor approved by the FDA for sale or use in the United States.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.